I AM NOT A FINANCIAL ADVISER! This is my attempt to better understand the cause/effect relationship of FDA Advisory Committee (AdComm) meetings on BioTech/Pharm stocks. This is for my own education, not to serve to advise or recommend any path for others. If looking for advice look elsewhere. If trying to understand the same stuff I’m trying to understand, please draw your own conclusions… mine are nuts, and would likely put you in the poor house.
Entire Webcast (third-party provider… costs money)
- Trading above my comfort level: $45 (at posting)
- Trading OTCMKTS on microscopic volume… it’s like it’s traded between cousins who rarely speak
- Quoth FDA Executive Summary document, page 20, section 5.6: “The pivotal clinical study does not meet all of the pre-specified primary performance objectives”
- I think I’m going to stay away from this
- … 5-4 say they Recommend Approval, forever changing my world view
|Date||Open||High||Low||Close||Change from Prior|
|3/27/2014||42.34||42.34||39.50||40.01||-1.74 (-4.168%) ?!?|
- There was a -3.923% drop on the Close of the Materials Release date from the prior Close… materials were released during the trading day.
- There was a -10.904% drop on the trading after the Materials Release date from the prior Close.
- Trading was not halted during AdComm.
- There was a -15.263% drop throughout the AdComm trading day, prior to any vote, and with limited access to Webcast.
- There was a -9.123% drop in Close from the first trading day after the successful AdComm vote.
- It’s difficult to imagine how the Markets would have reacted to a failed AdComm outcome.
- The five-day High was the High of the first trading day.
- The five-day High was the five-day Open.
- The five-day Low was the Low of the second trading day.
- The five-day Low was 14.124% lower than the five-day Open.